New acne pill enters early human testing
NCT ID NCT06989840
First seen Feb 02, 2026 · Last updated May 18, 2026 · Updated 19 times
Summary
This early-stage study tests a new oral drug, TVB-3567, in healthy volunteers (with or without acne) to see if it is safe and how the body processes it. The trial has four parts, including single and multiple doses, and a food-effect assessment. About 128 participants aged 18-55 will take either the drug or a placebo. The goal is to gather safety and dosing information before larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Celerion, Inc.
COMPLETEDTempe, Arizona, 85283, United States
-
Nucleus Network
RECRUITINGMelbourne, Victoria, 3004, Australia
Conditions
Explore the condition pages connected to this study.